JHVEPhoto/iStock Editorial via Getty Images
With the company’s Q1 2025 results on Tuesday, Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies, to the pipeline, following a major trial setback this month.
PFE shares came under pressure